🇺🇸 FDA
Pipeline program

Finerenone, Placebo, Placebo, BAY 94-8862

21177

Phase 3 small_molecule active

Quick answer

Finerenone, Placebo, Placebo, BAY 94-8862 for Non-diabetic chronic kidney disease is a Phase 3 program (small_molecule) at Bayer AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bayer AG
Indication
Non-diabetic chronic kidney disease
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials